Altamira Therapeutics (STU:2QA) ROCE % : -71.45% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Altamira Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Altamira Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2023 was -71.45%.

Altamira Therapeutics ROCE % Historical Data

The historical data trend for Altamira Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altamira Therapeutics ROCE % Chart

Altamira Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-112.46

-65.62

-43.24

-507.79

-2,401.09

Altamira Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															-2.34	-138.80	-2,207.52	-	-71.45

Altamira Therapeutics ROCE % Calculation

Altamira Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-6.615	/	( ( (6.387 - 13.051)	+	(8.158 - 0.943) )	/ 2 )
	=	-6.615	/	( (-6.664	+	7.215)	/ 2 )
	=	-6.615	/	0.2755
	=	-2,401.09 %

Altamira Therapeutics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-2.884	/	( ( (6.36 - 5.502)	+	(8.158 - 0.943) )	/ 2 )
	=	-2.884	/	( ( 0.858	+	7.215 )	/ 2 )
	=	-2.884	/	4.0365
	=	-71.45 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Altamira Therapeutics (STU:2QA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Altamira Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Altamira Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Altamira Therapeutics (STU:2QA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altamira Therapeutics Ltd (STU:2QA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CYTO:USA

Address

2 Church Street, Clarendon House, Hamilton, BMU, HM11

Website

https://www.altamiratherapeutics.com

Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens.

Altamira Therapeutics (STU:2QA) Headlines

No Headlines